Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xeris Pharmaceuticals Inc (NQ: XERS )

2.457 +0.197 (+8.73%)
Streaming Delayed Price Updated: 11:18 AM EDT, Jun 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Xeris Pharmaceuticals Inc

< Previous 1 2 3 Next >
Xeris Biopharma to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 10, 2021
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Pharmaceuticals Enters Collaboration Agreement With Merck
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Pharmaceuticals Completes Acquisition of Strongbridge Biopharma
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Xeris Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharma
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Xeris Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Xeris Pharmaceuticals Completes Enrollment of Its Phase 1 Study of Levothyroxine (XP-8121)
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Xeris Pharmaceuticals Announces Leading Independent Proxy Advisory Firm, ISS, Recommends Xeris Stockholders Vote “FOR” the Transaction With Strongbridge Biopharma
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Xeris Pharmaceuticals Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke® Kit for the Treatment of Severe Hypoglycemia
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Xeris Pharmaceuticals Strengthens Its Patent Estate
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Xeris Pharmaceuticals Achieves Unprecedented Levels of Payor Coverage for Gvoke®
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Xeris Pharmaceuticals Announces FDA Acceptance of its IND Application for XeriSol™ Levothyroxine (XP-8121) for the Treatment of Hypothyroidism
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Xeris Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Highlights
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Xeris Pharmaceuticals Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Xeris Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Xeris Pharmaceuticals Announces Executive Changes as Part of Its Strategy to Position the Company for Long-Term Commercial Success
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Xeris Pharmaceuticals Enters Into an Exclusive License and Supply Agreement with Tetris Pharma Limited to Commercialize Ogluo® in Europe
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Xeris Pharmaceuticals, Inc.
Via Business Wire
INVESTIGATION ALERT: Halper Sadeh LLP Investigates KSU, INSW, LMNX, XERS; Shareholders are Encouraged to Contact the Firm
NEW YORK, NY / ACCESSWIRE / May 27, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Kansas City Southern (NYSE:KSU) concerning... 
From Halper Sadeh LLP
Via AccessWire
Topics Fraud
Exposures Legal
Xeris Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Xeris Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – XERS
From Halper Sadeh LLP
Via Business Wire
Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Rule 2.5 Announcement: Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma Plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Xeris Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Highlights
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Xeris Pharmaceuticals to Webcast Upcoming Presentations
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Xeris Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 13, 2021
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Xeris Pharmaceuticals Announces Extension of the Interest-Only Period of Its Debt Facility With Oxford Finance and Silicon Valley Bank
From Xeris Pharmaceuticals, Inc.
Via Business Wire
NASDAQ:XERS Shareholder Notice: Investigation over Potential Wrongdoing at Xeris Pharmaceuticals, Inc.
San Diego, CA -- (SBWIRE) -- 05/05/2021 -- Certain directors of Xeris Pharmaceuticals, Inc. are under investigation over potential breaches of fiduciary duties. 
Via SBWire
Xeris Pharmaceuticals Receives U.K. MHRA Approval of Ogluo® (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus
From Xeris Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.